La catena delle opzioni mostra i dati chiave delle opzioni azionarie di KWESST Micro Systems a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per KWESST Micro Systems..

KWESST Micro Systems (NASDAQ:KWE) Azioni, Catena delle Opzioni

KWESST Micro Systems

KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.

KWESST Micro Systems Inc. - common stock, no R/S concurrent with offering

KWESST Micro Systems Inc

KraneShares Trust KraneShares CSI China Internet ETF

<p>Citigroup  analyst Steven Zaccone   maintains Advance Auto Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) with a Neutral and raises the price target from $44 to $47.</p>


News

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Advance Auto Parts, Raises Price Target to $47

<p>Morgan Stanley  analyst Matthew Cost   maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Overweight and raises the price target from $26 to $32.</p>


Morgan Stanley Maintains Overweight on Unity Software, Raises Price Target to $32

<p><strong>Trump Media and Technology Group Corp. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) has taken a major step by <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43879883/trump-media-board-votes-to-advance-expansion-plans" rel="noreferrer noopener">setting up a strategic acquisition fund</a>.</p>
<p>The Board of Directors approved this initiative, enabling the leadership to partner with chosen investors in creating a fund designed to support potential mergers and acquisitions.</p>
<p>The move aligns with TMTG&#8217;s broader growth objectives, targeting opportunities within the America First Economy.</p>
<p>The TMTG fund aims to pursue partnerships, mergers, or acquisitions with companies that complement its technology and brand.</p>
<p>&#8220;TMTG aims to grow robustly with great strategic partners who share our mission. We&#8217;re hoping to expand our tech footprint even as we branch out into finance and other industries,&#8221; said Chairman and CEO <strong>Devin Nunes</strong>.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43878300/netflix-invests-1b-in-mexican-film-industry" rel="noreferrer noopener">Netflix Bets Big On Mexico: Plans $1B Investment To Supercharge Local Productions</a></strong></p>
<p>&#8220;The America First economy is a fantastic sector with enormous potential, and we want all its participants to know that TMTG intends to make this market even greater.&#8221;</p>
<p>The objective is to transform TMTG into a holding company with several largely autonomous subsidiaries across various industries.</p>
<p>Recently, TMTG introduced its financial services division, Truth.Fi, which will offer tailored exchange-traded funds (ETFs) and separately managed accounts (SMAs).</p>
<p>These investment vehicles are part of a financial services and FinTech strategy approved by the Board, which involves a $250 million investment to be held by Charles Schwab.</p>
<p><strong>Price Action</strong>: DJT shares are trading lower by 0.32% at $27.75 at the last check Friday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios" target="_blank" rel="noreferrer noopener">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Equities

General

Trump Media's Strategic Fund Set To Fuel Mergers And Acquisitions: Details

<p>Citigroup  analyst David Lebowitz   maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Buy and raises the price target from $45 to $49.</p>


BBIO

Citigroup Maintains Buy on BridgeBio Pharma, Raises Price Target to $49

<p>Citigroup  analyst Ronald Josey   maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Buy and raises the price target from $5500 to $5800.</p>


BKNG

Citigroup Maintains Buy on Booking Holdings, Raises Price Target to $5800

<p>BMO Capital  analyst Brian Pitz   maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Outperform and raises the price target from $5155 to $5900.</p>


BMO Capital Maintains Outperform on Booking Holdings, Raises Price Target to $5900

<p><strong>Alibaba Group Holding</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) stock gained after multiple Wall Street firms raised their respective <a href="https://www.benzinga.com/quote/BABA/analyst-ratings" target="_blank" rel="noreferrer noopener">price targets on the stock on Friday</a>.</p>
<p>Among them was Benchmark analyst Fawne Jiang, who maintained a Buy rating on Alibaba with a price target of $190, up from $118.</p>
<p>Jiang noted that Alibaba is undergoing a long-awaited structural restructuring, driven by a rebound in its core e-commerce business, an improved earnings outlook thanks to better investment efficiency and growth reacceleration, and the recognition of asset value in key strategic areas such as AliCloud and Alibaba International Digital Commerce Group.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai" target="_blank" rel="noreferrer noopener">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a></strong></p>
<p>Despite strong stock performance year-to-date, Alibaba remains reasonably valued relative to global hyperscalers (~30x forward P/E). With the momentum of accelerated AI adoption in China, the analyst noted Alibaba as a leading player in China&#8217;s AI sector.</p>
<p>Alibaba&#8217;s third-quarter earnings checked all the boxes and more. This includes a notable reacceleration of growth across its core e-commerce and cloud businesses, a return to profit growth for Taobao and Tmall Group, and a clear pathway to profitability for AIDC and other loss-making assets.</p>
<p>More importantly, the drivers behind this core reacceleration appear sustainable, supported by a take rate increase for TTG and expedited adoption of AI Cloud.</p>
<p>To capitalize on this, Alibaba announced an aggressive capex plan, with total capex over the next three years set to exceed the past decade&#8217;s investments. This reflects both the surge in demand and the company&#8217;s determination to lead in this transformative era.</p>
<p>Jiang reiterated that full-stack service providers with strong infrastructure capabilities would be the primary beneficiaries.</p>
<p>Alibaba stands out with its competitive edge in infrastructure, proprietary models, and application capacity across diverse use cases.</p>
<p>While the stock has risen significantly in the past two months, Jiang noted that a structural rerating is driven by upward earnings revisions and multiple expansions catalyzed by technological innovations. Positive tariffs or macroeconomic developments could further enhance the upside potential.</p>
<p><strong>Price Action: </strong>BABA shares traded higher by 5.6% at $143.68 at the last check on Friday.</p>
<p><strong>Next Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43884588/alibaba-leads-china-stock-rally-as-deepseeks-ai-breakthrough-and-xis-support-boost-investor-confidence" target="_blank" rel="noreferrer noopener">US Listed China Stocks Rally: Alibaba&#8217;s Performance, President Xi&#8217;s Support, DeepSeek AI Boost Investor Confidence</a></strong></li>
</ul>
<p><em>Image by zhu difeng on Shutterstock</em>.</p>


Reiteration

Trading Ideas

BABA

Alibaba's AI Expansion, E-Commerce Growth Reinforce Bullish Analyst Outlook

<p>BMO Capital  analyst Jeffrey Silber   maintains Grand Canyon Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) with a Outperform and raises the price target from $181 to $202.</p>


LOPE

BMO Capital Maintains Outperform on Grand Canyon Education, Raises Price Target to $202

<p>RBC Capital  analyst Michael Carroll   maintains CareTrust REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRE#NYSE">CTRE</a>) with a Outperform and lowers the price target from $37 to $32.</p>


CTRE

RBC Capital Maintains Outperform on CareTrust REIT, Lowers Price Target to $32

<p>Maxim Group  analyst Allen Klee   maintains Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) with a Buy and raises the price target from $54 to $75.</p>


INOD

Maxim Group Maintains Buy on Innodata, Raises Price Target to $75

<p>BMO Capital  analyst Kelly Bania   maintains Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) with a Market Perform and raises the price target from $140 to $180.</p>


BMO Capital Maintains Market Perform on Sprouts Farmers Market, Raises Price Target to $180

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Freshpet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FRPT, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 30 uncommon options trades for Freshpet.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $370,105, and 24 are calls, for a total amount of $3,593,450.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $140.0 for Freshpet over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Freshpet's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freshpet's whale trades within a strike price range from $50.0 to $140.0 in the last 30 days. </p>
<h3>Freshpet 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740159935_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$56.1</td>
<td>$54.0</td>
<td>$56.0</td>
<td>$50.00</td>
<td>$560.0K</td>
<td align="right">6</td>
<td align="right">669</td>
</tr>
<tr>
<td>FRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$56.1</td>
<td>$54.1</td>
<td>$56.0</td>
<td>$50.00</td>
<td>$560.0K</td>
<td align="right">6</td>
<td align="right">466</td>
</tr>
<tr>
<td>FRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$56.0</td>
<td>$52.0</td>
<td>$56.0</td>
<td>$50.00</td>
<td>$481.6K</td>
<td align="right">6</td>
<td align="right">267</td>
</tr>
<tr>
<td>FRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$56.0</td>
<td>$52.8</td>
<td>$56.0</td>
<td>$50.00</td>
<td>$420.0K</td>
<td align="right">6</td>
<td align="right">253</td>
</tr>
<tr>
<td>FRPT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$57.4</td>
<td>$56.0</td>
<td>$56.0</td>
<td>$50.00</td>
<td>$218.4K</td>
<td align="right">6</td>
<td align="right">142</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freshpet</h3>
<p>Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. The former two store types accounted for 89% of 2023 sales, with grocery stores representing the primary driver of footprint growth. Freshpet primarily targets dogs (92% of sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 96% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.</p>
<p>Having examined the options trading patterns of Freshpet, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Freshpet</h3>
<ul>
<li>With a volume of 1,761,122, the price of FRPT is down -5.95% at $100.06. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 73 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freshpet</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $149.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Freshpet, targeting a price of $160.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Freshpet with a target price of $142.<br />
&#x2A; An analyst from Stifel persists with their Buy rating on Freshpet, maintaining a target price of $155.<br />
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Freshpet, which currently sits at a price target of $142. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Freshpet with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

FRPT

Decoding Freshpet's Options Activity: What's the Big Picture?

<p>Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Biogen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 27% bearish. Among these notable options, 3 are puts, totaling $154,362, and 8 are calls, amounting to $325,022.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $155.0 for Biogen over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Biogen's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale trades within a strike price range from $120.0 to $155.0 in the last 30 days. </p>
<h3>Biogen Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740159930_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.7</td>
<td>$9.5</td>
<td>$9.7</td>
<td>$135.00</td>
<td>$72.7K</td>
<td>479</td>
<td align="right">1</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.3</td>
<td>$5.1</td>
<td>$5.2</td>
<td>$140.00</td>
<td>$52.0K</td>
<td>122</td>
<td align="right">113</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$20.5</td>
<td>$19.9</td>
<td>$20.5</td>
<td>$120.00</td>
<td>$51.2K</td>
<td>1.0K</td>
<td align="right">115</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$9.7</td>
<td>$9.6</td>
<td>$9.7</td>
<td>$150.00</td>
<td>$49.4K</td>
<td>119</td>
<td align="right">3</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$12.6</td>
<td>$11.9</td>
<td>$12.3</td>
<td>$130.00</td>
<td>$49.2K</td>
<td>149</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>Having examined the options trading patterns of Biogen, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Biogen Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 601,076, the BIIB's price is up by 2.28%, now at $140.21. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>Professional Analyst Ratings for Biogen</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $170.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Biogen, targeting a price of $224.<br />
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Biogen with a target price of $145.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Biogen with a target price of $210.<br />
&#x2A; An analyst from BMO Capital persists with their Market Perform rating on Biogen, maintaining a target price of $139.<br />
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $135.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


BIIB

Biogen Options Trading: A Deep Dive into Market Sentiment

<p>BMO Capital  analyst Brian Pitz   maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Market Perform and raises the price target from $50 to $55.</p>


BMO Capital Maintains Market Perform on Wayfair, Raises Price Target to $55

<p>Deep-pocketed investors have adopted a bullish approach towards D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in QBTS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for D-Wave Quantum. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 61% leaning bullish and 33% bearish. Among these notable options, 6 are puts, totaling $372,658, and 12 are calls, amounting to $484,395.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $2.0 and $11.0 for D-Wave Quantum, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for D-Wave Quantum options trades today is 4170.13 with a total volume of 8,569.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for D-Wave Quantum's big money trades within a strike price range of $2.0 to $11.0 over the last 30 days.</p>
<h3>D-Wave Quantum Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740159925_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$1.0</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$8.00</td>
<td>$160.4K</td>
<td>218</td>
<td>0</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.9</td>
<td>$1.85</td>
<td>$1.85</td>
<td>$7.00</td>
<td>$69.3K</td>
<td>8.4K</td>
<td>376</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.7</td>
<td>$0.6</td>
<td>$0.66</td>
<td>$8.50</td>
<td>$66.0K</td>
<td>333</td>
<td>1.0K</td>
</tr>
<tr>
<td>QBTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.8</td>
<td>$0.75</td>
<td>$0.78</td>
<td>$8.00</td>
<td>$58.5K</td>
<td>1.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>QBTS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.9</td>
<td>$2.0</td>
<td>$2.6</td>
<td>$8.00</td>
<td>$52.0K</td>
<td>735</td>
<td>0</td>
</tr>
</tbody>
</table>
</p>
<h3>About D-Wave Quantum</h3>
<p>D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the Company's LeapTM cloud service.</p>
<h3>Where Is D-Wave Quantum Standing Right Now?</h3>
<ul>
<li>With a volume of 63,792,645, the price of QBTS is up 1.83% at $7.53. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 34 days.</li>
</ul>
<h3>What Analysts Are Saying About D-Wave Quantum</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $11.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B. Riley Securities has decided to maintain their Buy rating on D-Wave Quantum, which currently sits at a price target of $11. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for D-Wave Quantum, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


QBTS

Unpacking the Latest Options Trading Trends in D-Wave Quantum

<p>Maxim Group  analyst Tate Sullivan   maintains NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) with a Buy and maintains $24 price target.</p>


NVEE

Maxim Group Maintains Buy on NV5 Global, Maintains $24 Price Target

<p>RBC Capital  analyst Mike Dahl   maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Outperform and lowers the price target from $167 to $162.</p>


BLDR

RBC Capital Maintains Outperform on Builders FirstSource, Lowers Price Target to $162

Live On CNBC, Jim Lebenthal Announces Sold Deere & Company

<p>BMO Capital  analyst Keith Bachman   maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and lowers the price target from $425 to $375.</p>


BMO Capital Maintains Outperform on Salesforce, Lowers Price Target to $375

<p>Maxim Group  analyst Michael Diana   initiates coverage on Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) with a Buy rating and announces Price Target of $7.</p>


Initiation

Mobile Infrastructure Corporation Common Stock

Comments

KWESST Micro Systems

KWESST Micro Systems (KWE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO